[go: up one dir, main page]

BRPI0816513A2 - Composição farmacêutica e método para preparar a suspensão sólida - Google Patents

Composição farmacêutica e método para preparar a suspensão sólida

Info

Publication number
BRPI0816513A2
BRPI0816513A2 BRPI0816513A BRPI0816513A2 BR PI0816513 A2 BRPI0816513 A2 BR PI0816513A2 BR PI0816513 A BRPI0816513 A BR PI0816513A BR PI0816513 A2 BRPI0816513 A2 BR PI0816513A2
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutical composition
solid suspension
suspension
solid
Prior art date
Application number
Other languages
English (en)
Inventor
Markus Thommes
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of BRPI0816513A2 publication Critical patent/BRPI0816513A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0816513 2007-10-19 2008-10-17 Composição farmacêutica e método para preparar a suspensão sólida BRPI0816513A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98118507P 2007-10-19 2007-10-19
US3894308P 2008-03-24 2008-03-24
PCT/US2008/080327 WO2009052391A1 (en) 2007-10-19 2008-10-17 Solid formulations of crystalline compounds

Publications (1)

Publication Number Publication Date
BRPI0816513A2 true BRPI0816513A2 (pt) 2015-03-24

Family

ID=40567797

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816513 BRPI0816513A2 (pt) 2007-10-19 2008-10-17 Composição farmacêutica e método para preparar a suspensão sólida

Country Status (10)

Country Link
US (1) US20100222311A1 (pt)
EP (1) EP2214635A1 (pt)
JP (1) JP2011500724A (pt)
CN (1) CN101896161A (pt)
AU (1) AU2008312321A1 (pt)
BR (1) BRPI0816513A2 (pt)
CA (1) CA2702935A1 (pt)
IL (1) IL205130A0 (pt)
MX (1) MX2010004222A (pt)
WO (1) WO2009052391A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR DARMFLORA TRANSPLANTATION AND METHOD FOR THE PRODUCTION AND USE THEREOF, AND METHOD FOR THEIR ADMINISTRATION
DK2651415T3 (da) 2010-12-13 2020-11-30 Rite Prep Pty Ltd Mave- og tyktarmsformuleringer og fremgangsmåder til fremstilling og brug af dem
BR112013021030A2 (pt) * 2011-02-17 2016-10-11 Hoffmann La Roche processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
EP3135291A1 (en) 2011-03-09 2017-03-01 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104540521A (zh) 2012-06-04 2015-04-22 高拉夫·阿格拉沃尔 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法
KR102152873B1 (ko) 2012-07-27 2020-09-08 레드힐 바이오파마 엘티디 결장 배출의 용도를 위한 제형 및 제형의 제조 방법
US20160089363A1 (en) 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US11045401B2 (en) 2013-07-24 2021-06-29 Heartland Consumer Products Llc Partial melt co-crystallization compositions
US11839698B2 (en) 2014-03-13 2023-12-12 W. L. Gore & Associates, Inc. Drug composition and coating
MX381237B (es) 2015-03-03 2025-03-12 Heartland Consumer Products Llc Composiciones edulcorantes que contienen rebaudiósidos d.
JP6692897B2 (ja) 2015-05-14 2020-05-13 クレストヴォ・ホールディングス・エルエルシー 便フローラを移植するための組成物、並びにそれを調製及び使用する方法、並びにそれを送達するためのデバイス
ES2909456T3 (es) 2015-05-22 2022-05-06 Univ Arizona State Métodos para tratar el trastorno del espectro autista y síntomas asociados
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
US11214773B2 (en) 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
AU2018250206A1 (en) 2017-04-05 2019-10-31 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (PD) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CN110621305A (zh) 2017-07-24 2019-12-27 爱科思华制药研发有限责任公司 高载药量药物组合物
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
EP3511001B1 (en) * 2018-01-12 2021-09-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Pirfenidone-containing tablet and capsule formulation
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
EP3866923A1 (en) * 2018-10-17 2021-08-25 Sandoz AG Co-crystals comprising levothyroxine and a dicarboxylic acid
WO2020210205A1 (en) * 2019-04-08 2020-10-15 Cosci Med-Tech Co., Ltd Methods of improving pharmaceutical substance solubilization and products thereof
CN115944654A (zh) 2019-07-19 2023-04-11 芬奇治疗控股有限责任公司 用于治疗胃肠道病症的方法及产品
CN116033891A (zh) * 2020-09-03 2023-04-28 菲利普莫里斯生产公司 冷冻干燥的低吸湿性活性粉末组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5075291A (en) * 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
HUT59653A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing complexes containing s/+/-phenyl-alcanoic acids and alpha-hydroxy-alcanoic acids and pharmaceutical compositions containing them as active components
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
EP1390063B1 (en) * 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
BRPI0407181A (pt) * 2003-02-03 2006-02-07 Novartis Ag Formulação farmacêutica
RU2343905C2 (ru) * 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Твердые дозированные формы, включающие фибрат и статин
WO2005105102A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition

Also Published As

Publication number Publication date
WO2009052391A1 (en) 2009-04-23
AU2008312321A1 (en) 2009-04-23
EP2214635A1 (en) 2010-08-11
JP2011500724A (ja) 2011-01-06
CA2702935A1 (en) 2009-04-23
IL205130A0 (en) 2010-11-30
CN101896161A (zh) 2010-11-24
US20100222311A1 (en) 2010-09-02
MX2010004222A (es) 2010-09-14

Similar Documents

Publication Publication Date Title
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0815138A2 (pt) Métodos e organismos para a produção acoplada a crescimento de 1,4-butanodiol
BRPI0818430A2 (pt) Composição antiperspirante sólida e método para a produção da mesma
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0814153A2 (pt) "método para preparar um composto e composto"
BRPI0919199A2 (pt) suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas
BRPI0817727A2 (pt) composição de graxa lubrificante, e, método para preparar uma composição de graxa
GB2456752B (en) Agrochemical composition and method for preparing the same
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0813774B8 (pt) produto microencapsulado, método para preparar o mesmo, e, produto consumível
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0819020A2 (pt) "método e sistema para criar uma peça"
FI20075533L (fi) Hiomatuote ja menetelmä tämän valmistamiseksi
DK2140867T4 (da) Farmaceutisk sammensætning
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI0812647A2 (pt) "composição e método para produzir a composição"
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
BRPI0720530A2 (pt) Partícula, processo para preparar a partícular, e, composição
BRPI0720705A2 (pt) Método para preparar uma composição de espumação, e, composição de espumação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.